European EMA removes about 100 generic drugs
- “Miracle Weight-Loss Drug” Sweeps Across America
- The United States Avian Influenza Outbreak Worse Than Expected?
- Global First: Bovine Avian Influenza Transmission to Humans Detected
- Potassium-Enriched Salt Substitutes: Reducing Blood Pressure Risk?
- Tritium Detection in Fukushima’s Seawater: Below Safety Standards
- What Reason Let AstraZeneca Withdraws COVID Vaccine From The Market?
European EMA removes about 100 generic drugs involving Johnson & Johnson, Sandoz, Teva, etc.
- AstraZeneca Admits for the First Time that its COVID Vaccine Has Blood Clot Side Effects
- Was COVID virus leaked from the Chinese WIV lab?
- HIV Cure Research: New Study Links Viral DNA Levels to Spontaneous Control
- FDA has mandated a top-level black box warning for all marketed CAR-T therapies
- Can people with high blood pressure eat peanuts?
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
European EMA removes about 100 generic drugs involving Johnson & Johnson, Sandoz, Teva, etc.
A few days ago, the European Medicines Agency (EMA) recommended that European countries suspend the use of about 100 generic drugs.
The European EMA said in a statement that up to 100 generic drugs were recommended to be discontinued this time, mainly because after testing a generic drug from an India-based CRO company, it found that the CRO company’s trial data had integrity problems and even may be suspected of fraud.
The issue has also raised serious concerns about the Indian company’s quality management system and the reliability of data on the company’s website.
Generic companies affected by the European EMA’s decision include Johnson & Johnson, Sandoz, Viatris, Teva, Jubilant, Wockhardt, Accord Healthcare, Aurora Biofarma, Strides Pharma, Tillomed Pharma, Orifarm Generics, Stada, Brillpharma, Micro Labs, ratiopharm , Bennet Pharmaceutica, Medicair Bioscience Laboratories, Pinewood, etc.
It’s worth noting that Synchron Research Services, which is the subject of this outbreak, is not the first CRO company to come under the spotlight for data problems.
Similar problems have occurred with trial data from several Indian CROs, including Semler Research and GVK Biosciences, previously targeted by the US FDA and European EMA.
As was the case with Synchron, regulators also required Semler to repeat the bioequivalence/bioavailability study at an acceptable alternative study site.
And last September, Synchron also came under fire from the FDA for similar data issues.
According to a previous FDA notice to Synchron, the regulator found the company had an abnormal and unexplained record of research that indicated that Synchron engaged in practices and processes that undermined the reliability of analytical methods.
The FDA said, “After careful review of your company’s research records, it was concluded that these practices and processes meant that you submitted falsified research data to the FDA.”
In addition to this, the European and American EMA warned member states that the drugs proposed to be suspended this time “may have crucial effects in certain EU member states”, such as the lack of available alternatives.
Therefore, for the benefit of patients, national authorities can temporarily postpone the decision to suspend the use of the drug.
In addition, Member States should also decide whether the affected drugs need to be recalled within their territories.
Reference source:
Europe to suspend about 100 generic drugs after uncovering data ‘irregularities’ at Indian CRO
European EMA removes about 100 generic drugs involving Johnson & Johnson, Sandoz, Teva, etc.
(source:internet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.